Safety and efficacy of ruxolitinib cream for the treatment of vitiligo: A randomised controlled trial secondary analysis at 3 years
Skin Health Dis
.
2024 Aug 7;4(6):e404.
doi: 10.1002/ski2.404.
eCollection 2024 Dec.
Authors
John E Harris
1
,
Amit G Pandya
2
3
,
Mark Lebwohl
4
,
Iltefat H Hamzavi
5
,
Pearl Grimes
6
,
Alice B Gottlieb
4
,
Howard L Sofen
7
,
Angela Y Moore
8
9
,
Mingyue Wang
10
,
Deanna Kornacki
10
,
Kathleen Butler
10
,
David Rosmarin
11
Affiliations
1
University of Massachusetts Chan Medical School Worcester Massachusetts USA.
2
Palo Alto Foundation Medical Group Sunnyvale California USA.
3
University of Texas Southwestern Medical Center Dallas Texas USA.
4
Icahn School of Medicine at Mount Sinai New York New York USA.
5
Henry Ford Medical Center Detroit Michigan USA.
6
The Vitiligo & Pigmentation Institute of Southern California Los Angeles California USA.
7
David Geffen UCLA School of Medicine Los Angeles California USA.
8
Arlington Research Center Arlington Texas USA.
9
Baylor University Medical Center Dallas Texas USA.
10
Incyte Corporation Wilmington Delaware USA.
11
Indiana University School of Medicine Indianapolis Indiana USA.
PMID:
39624731
PMCID:
PMC11608864
DOI:
10.1002/ski2.404
No abstract available